METHODS OF THERAPY FOR CANCERS EXPRESSING THE CD40 ANTIGEN

(19)

(11)

EP 1 682 178 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	01.09.2010 Bulletin 2010/35

(45)	Mention of the grant of the patent:
	07.07.2010 Bulletin 2010/27

(21)	Application number: 04810421.0

(22)	Date of filing: 04.11.2004

(51)

International Patent Classification (IPC):

A61K 39/395^(2006.01)
A61P 35/02^(2006.01)

A61K 38/20^(2006.01)

(86)	International application number:
	PCT/US2004/036958

(87)	International publication number:
	WO 2005/044294 (19.05.2005 Gazette 2005/20)

(54)	METHODS OF THERAPY FOR CANCERS EXPRESSING THE CD40 ANTIGEN VERFAHREN ZUR BEHANDLUNG VON KREBS MIT EXPRESSION DES CD40-ANTIGENS PROCEDES DE THERAPIE POUR DES CANCERS EXPRIMANT L'ANTIGENE CD40

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

(30)

Priority:

04.11.2003 US 517337 P
26.11.2003 US 525579 P
27.04.2004 US 565710 P

(43)	Date of publication of application:
	26.07.2006 Bulletin 2006/30

(60)	Divisional application:
	10006780.0

(73)	Proprietors:
	Novartis Vaccines and Diagnostics, Inc. Emeryville, CA 94608 (US) XOMA Technology Ltd. Hamilton HM11 (BM)

(72)	Inventors:
	LONG, Li Emeryville, CA 94662-8097 (US) LUQMAN, Mohammad Emeryville, CA 94662-8097 (US) YABANNAVAR, Asha Emeryville, CA 94662-8097 (US) ZAROR, Isabel Emeryville, CA 94662-8097 (US) HURST, Deborah Emeryville, CA 94662-8097 (US) LOPES DE MENEZES, Daniel, E. Emeryville, CA 94662-8097 (US)

(74)	Representative: Marshall, Cameron John et al
	Carpmaels & Ransford One Southampton Row London WC1B 5HA London WC1B 5HA (GB)

(56)

References cited: :

WO-A-01/83755
WO-A-02/28904

WO-A-02/28480
WO-A-02/088186

GISSELBRECHT CHRISTIAN ET AL: "Interleukin-2 treatment in lymphoma: A phase II multicenter study" BLOOD, vol. 83, no. 8, 1994, pages 2081-2085, XP002327659 ISSN: 0006-4971 cited in the application
ROSENBERG S A ET AL: "A PROGRESS REPORT ON THE TREATMENT OF 157 PATIENTS WITH ADVANCES CANCER USING LYMPHOKINE-ACTIVATED KILLER CELLS AND INTERLEUKIN-2 OR HIGH-DOSE INTERLEUKIN-2 ALONE" NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 316, no. 15, 2 April 1987 (1987-04-02), pages 889-897, XP001118518 ISSN: 0028-4793 cited in the application
LITTLE M. ET AL: 'Of mice and men: hybridoma and recombinant antibodies' REVIEW IMMUNOLOGY TODAY vol. 21, no. 8, August 2000, pages 364 - 370
ELLMARK PETER ET AL: 'Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library' IMMUNOLOGY vol. 106, 2002, pages 456 - 463

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).